Landscapes / Targets
NLRP3
4 drugs act on NLRP3, in 5 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs4
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2/3 | 31 Dec 2026Phase 2/3 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Acute Gout Flare, Gout Attack and 5 more | ||||
| Open drug page | |||||
NLRP3 inhibitor unconfirmed |
BioAge Labs · Public BIOA |
Phase 2 | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks NLRP3 | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Obesity and Cardiovascular Risk, Diabetic Macular Edema (DME) | ||||
| Open drug page | |||||
— |
Phase 2 | Mar 2028Phase 2 trial completes | |||
| Next date | Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Amyotrophic Lateral Sclerosis (ALS) | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Parkinson Disease | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 4 of 4 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026